BSR’s review of industry-led health partnerships

Introduction
Why GHPs?

GHPs are growing…

…recognizing key benefits

- Extending reach and scale
- Sharing or reducing risks
- Sharing knowledge and resources to improve effectiveness
- Reducing duplication of investment or activities

GHPs bring together complementary assets and capabilities to solve systemic global health challenges
UN Global Compact (UNGC) LEAD’s typology for PPPs

UN Global Compact Criteria for Transformational Partnerships
(specific to GHPs as a type of partnership)

- Are GHPs addressing systemic issues?
- Are GHPs involving the appropriate stakeholders?
- Do GHPs have capacity to reach scale and have lasting impact?
- Are GHPs leveraging the core competencies of all partners?
GHPs are meeting unmet health needs

**GHPs by therapeutic area**

- **HIV/AIDS**: 25% of GHPs surveyed
- **NTDs**: 20% of GHPs surveyed
- **Women/Childcare**: 15% of GHPs surveyed
- **NCDs**: 10% of GHPs surveyed
- **Malaria**: 10% of GHPs surveyed
- **Tuberculosis**: 10% of GHPs surveyed
- **General Health**: 10% of GHPs surveyed
- **Preventable**: 5% of GHPs surveyed

NCDs are already in focus for GHPs…

…40% of companies expect to increase commitments to NCD-related GHPs in next five years

**Current distribution of GHPs is focused on Africa…**

**…but next five years will see growth in Asia and Latin America**

- High coverage (> 50% of GHPs)
- Medium coverage (26-50% of GHPs)
- Low coverage (11-25% of GHPs)
Health systems capacity building

Focus areas of GHPs

59% focus on strengthening health system infrastructures…

…79% of those are focused on training

30% of GHPs focus on research and development, broadly speaking

10% of GHPs focus on building local research capacity

R&D focus areas of GHPs

% of GHPs surveyed
0 10 20 30 40 50 60 70
Health System Infrastructure Prevention, Awareness & Outreach Availability of Treatment Research & Development

% of R&D Partnerships
0 10 20 30 40 50 60 70
Treatments Research Capacity Pediatric
Expanding global health collaborations

Distribution of partners in GHPs

- NGOs and Government stakeholders are well represented in GHPs…
- …but only 15% of companies engage with other MNCs in GHPs
- 65% expect to move toward multicompany partnerships in the next five years

Next steps in expanding multi-company partnerships

- Define roles for private sector participants
- Lower barriers to collaboration
- Lead the way, and ask other companies to follow your example
Leveraging a full range of Assets

**Assets leveraged by the private sector in supporting GHPs**

- **Cash & Product** (e.g., London Declaration)
- **Employee Skills & Time** (e.g., Pfizer Global Health Fellows)
- **R&D Capabilities** (e.g., Sanofi/DNDi development of ASAQ)

---

**Enabling Environment**

Leveraging critical assets from other sectors, i.e., government, multilateral organizations and civil society.
Recognizing successes & mapping our journey ahead

Are GHPs addressing systemic issues?  ✔️

Are GHPs involving the appropriate stakeholders?  ✔️

Are GHPs leveraging the core competencies of all partners?  ✔️

Do GHPs have an capacity to reach scale and have lasting impact?  ❓

Working towards improved impact measurement

• Agree standard framework
• Establish a baseline
• Working towards understanding final health outcomes

• Improve internal company systems
• Build capacity of local partners
• Communicate results
THANK YOU